内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

JCLA：甲状旁腺切除术可降低血清完整甲状旁腺激素和钙的水平，延长老年血液透析患者严重继发性甲状旁腺功能亢进的总体生存期？

2019-07-14 Gladiator MedSci原创

甲状旁腺功能亢进
关注

本研究的目的是评估甲状旁腺切除术(PTX)治疗对老年血液透析合并严重继发性甲状旁腺功能亢进(SHPT)患者延长总生存期(OS)和降低完整甲状旁腺激素(iPTH)、钙(Ca)和磷(P)水平的影响。 本队列研究连续纳入304例老年血液透析合并重度SHPT患者。根据是否行PTX手术，将患者分为PTX组(N = 112)和对照组(N = 192)，随访3年。进而，评估死亡率和OS，记录iPTH、Ca

本研究的目的是评估甲状旁腺切除术(PTX)治疗对老年血液透析合并严重继发性甲状旁腺功能亢进(SHPT)患者延长总生存期(OS)和降低完整甲状旁腺激素(iPTH)、钙(Ca)和磷(P)水平的影响。

本队列研究连续纳入304例老年血液透析合并重度SHPT患者。根据是否行PTX手术，将患者分为PTX组(N = 112)和对照组(N = 192)，随访3年。进而，评估死亡率和OS，记录iPTH、Ca和P水平。

研究发现，与对照组相比，PTX组在基线时iPTH升高(P < 0.001)， Ca升高(P = 0.003)， AST升高(P = 0.022)， Hb降低(P = 0.049)。与对照组相比，PTX组1年死亡率(P < 0.001)、2年死亡率(P < 0.001)和3年死亡率(P < 0.001)均降低，PTX与OS延长相关(P < 0.001)。多因素Cox回归分析进一步揭示PTX治疗(P < 0.001, HR = 0.177)是改善OS的独立因素。此外，在M1‐M36时，PTX组患者的iPTH (P < 0.05)和Ca (P < 0.05)水平均低于对照组，而在M1‐M36时，两组患者血清P水平无差异。

研究表明，甲状旁腺切除术可降低iPTH和Ca水平，并与老年血液透析患者严重SHPT的良好生存率相关。

原始出处：

Jinnan Wan , Wenhuan Li ,Parathyroidectomy decreases serum intact parathyroid hormone and calcium levels and prolongs overall survival in elderly hemodialysis patients with severe secondary hyperparathyroidism

本文系梅斯医学（MedSci）原创编译整理，转载需授权！



版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2020-03-26 feifers

    #继发#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2020-03-15 xzw113

    #继发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-11-04 doctorzheng

    #切除术#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 habb

    #血液透析#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 juliusluan78

    #生存期#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 仁医06

    #甲状旁腺功能亢进#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 huperzia

    #甲状旁腺#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 xre2010

    #甲状旁腺切除术#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 swallow

    #总体生存期#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1724497, encodeId=4b8c1e24497a8, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 26 16:27:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952682, encodeId=0e861952682b7, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sun Mar 15 11:27:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877176, encodeId=a98318e717698, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Nov 04 19:27:00 CST 2019, time=2019-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262541, encodeId=80a412625411c, content=<a href='/topic/show?id=a57589339a4' target=_blank style='color:#2F92EE;'>#血液透析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89339, encryptionId=a57589339a4, topicName=血液透析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378218, encodeId=a5c113e821867, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379546, encodeId=a0cb13e95462f, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452474, encodeId=e20d14524e454, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469801, encodeId=b4431469801f8, content=<a href='/topic/show?id=3e166982eb8' target=_blank style='color:#2F92EE;'>#甲状旁腺切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69827, encryptionId=3e166982eb8, topicName=甲状旁腺切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9a6a7064699, createdName=xre2010, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530816, encodeId=e58f153081679, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570647, encodeId=23b115e06470b, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Tue Jul 16 14:27:00 CST 2019, time=2019-07-16, status=1, ipAttribution=)]
    2019-07-16 ewsr6

    #透析患者#

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

JASN：肾移植术后甲状旁腺功能亢进：手术比药物更有效

一项由Bellvitge生物医学研究所肾脏病学组（IDIBELL）和Bellvitge大学附属医院（HUB）的研究人员领导的一项研究，比较了三发性甲状旁腺功能亢进即肾脏移植后手术 vs 药物治疗的结果。该研究结果已发表在影响最大的Journal of the American Society of Nephrology杂志上。这是第一个比较该疾病这两种治疗方法的临床试验，并由卡洛斯三世卫生研究所自

2016AAES指南——原发性甲状旁腺功能亢进管理发布

2016年8月，美国内分泌外科协会(AAES)发布了原发性甲状旁腺机能亢进的管理指南，原发性甲状旁腺功能亢进是一个常见的临床问题，其明确的治疗方法是手术切除，本文主要针对甲状旁腺切除术的相关问题提供了循证指导，以帮助临床医生优化此类患者的临床管理。全文获取：下载地址：指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)

原发性甲状旁腺功能亢进伴单侧眼球突出

 一位27岁女性因双侧肾结石和轻微外伤引起的右侧胫骨骨折来就诊。体格检查：血压124/80 mm Hg，甲状腺I度弥漫性肿大。右眼球突出(23 mm)，临床活动度评分为0/7（图 1A），无甲状腺功能亢进的特征。未触及骨肿胀或咖啡牛奶斑。实验室检查：血清钙是3.25 mmol/l (正常为2.15–2.55 mmol/l)，无机磷0.77 mmol/l (0.87–1.39 mmol/l

FDA暂停盐酸西那卡塞儿童试验

　　根据2013年2月26日美国食品与药物管理局（FDA）官方网站消息，FDA已暂停了盐酸西那卡塞(商品名Sensipar，通用名cinacalcet hydrochloride)的所有儿童试验，原因是最近出现了14岁儿童死亡案例。目前尚未确定西那卡塞是否导致了患者死亡。 　　FDA建议，医生应监测患者的血清钙水平。在启动盐酸西那卡塞治疗或调整其剂量后1周内评估患者的血清钙水平，

JCEM：正常范围上限的血清PTH水平与心血管疾病相关

越来越多的证据表明甲状旁腺功能亢进与心血管疾病发病率和死亡率风险增加有关。然而，关于正常范围血清甲状旁腺素（PTH）水平与心血管疾病（CVD）的关系所知甚少。为研究正常水平血清PTH与CVD和腹主动脉钙化（AAC）的关系，来自荷兰阿姆斯特丹自由大学医学中心的Elisabeth M Eekhoff教授及其团队进行了一项研究，发现血清PTH水平处于正常范围上限与CVD高度相关。该研究结果在线发表于20

HIFU在尿毒症继发性甲状旁腺功能亢进中的治疗

    最近开发的为破坏甲状旁腺腺瘤的非侵入性的高强度聚焦超声（HIFU）技术可能对慢性肾脏疾病继发的甲状旁腺功能亢进（SHP）患者的治疗也是有益的。我们使用这种方法进行了试验研究。       研究者对5位慢性血液透析患者合并有严重的继发性甲状旁腺功能亢进，分别接受1至3次高强度聚焦超声治疗。接受这种治疗的患者均至少有一个或两个肿大的甲状旁腺